AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer
Status:
Completed
Trial end date:
2013-08-27
Target enrollment:
Participant gender:
Summary
Background:
- The experimental cancer treatment drug AZD6244 has been shown to block signals that tell
cancer cells to grow. Cetuximab, a drug approved to treat cancer of the head, neck, colon,
and rectum, also blocks signals that tell cancer cells to grow. Researchers are investigating
the highest safe dose of AZD6244 to give with cetuximab, and will also investigate the
effectiveness of this drug combination in individuals who have colorectal cancer that
involves a particular protein known as the K-RAS protein. Cetuximab is not used to treat
colorectal cancer with K-RAS tumors because it has not been shown to be effective, but
researchers believe that adding AZD6244 to cetuximab may improve how well cetuximab works,
even in people with K-RAS tumors.
Objectives:
- To evaluate the safety and effectiveness of AZD6244 in combination with cetuximab for
solid tumors that have not responded to standard treatment.
- To evaluate the safety and effectiveness of AZD6244 in combination with cetuximab for
colorectal cancer that involves the K-RAS protein and has not responded to standard
treatment.
Eligibility:
- Individuals at least 18 years of age who have been diagnosed with solid tumors that have
not responded to standard treatment.
- Individuals at least 18 years of age who have been diagnosed with colorectal cancer that
has not responded to standard treatment.
Design:
- This protocol will involve two separate studies: an initial study to establish the
highest safe and effective dose of AZD6244 and cetuximab in individuals with solid
tumors, and an expansion study of AZD6244 and cetuximab in individuals with colorectal
cancer involving the K-RAS protein.
- Participants will be screened with a full medical history and physical examination,
blood samples, imaging studies, and other tests as required by the researchers.
- AZD6244 is a capsule to be swallowed once or twice a day, every day, with water on an
empty stomach. Cetuximab will be given intravenously once a week, over 2 hours for the
first dose and over an hour for every following dose. This combination of daily AZD6244
and weekly cetuximab will be repeated in 28-day cycles of treatment. Participants will
keep a diary to record the time of taking AZD6244 each day, as well as any side effects.
- Participants will have frequent blood tests and other exams during the first cycle of
treatment, up to five visits to the National Institutes of Health (NIH) and other visits
to their local doctor to in the first 28-day cycle.
- During subsequent cycles, participants will have four visits to NIH and four visits to
your local doctor for examinations, blood tests, and imaging studies.
- Participants may continue to receive the AZD6244 with cetuximab for up to 6 cycles,
until the tumor grows, unacceptable side effects development, or the participant or
participant's doctor decides to stop participation. There will be a final study visit
that repeats the procedures performed during the screening visit....